Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP

FEMS Immunology and Medical Microbiology

Volumn 40, Issue 1, 2004, Pages 57-61

  Ribeiro, Marcelo L ^a   Gerrits, Monique M ^b   Benvengo, Yune H B ^a   Berning, Marco ^b   Godoy, Anita P O ^a   Kuipers, Ernst J ^b   Mendonça, Sergio ^a   Van Vliet, Arnoud H M ^b   Pedrazzoli Jr , José ^a   Kusters, Johannes G ^b  

^a S Francisco Univ Medical School   (Brazil)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antibiotic resistance; Gastric disease; Helicobacter pylori; Peptic ulcer; Polymerase chain reaction restriction fragment length polymorphism; Tetracycline

Indexed keywords

TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOASSAY; CONTROLLED STUDY; DRUG EFFICACY; HELICOBACTER PYLORI; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RNA GENE;

EID: 9144250989     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(03)00277-3     Document Type: Article

References (22)

1. Dunn B.E., Cohen H., Blaser M.J. Helicobacter pylori. Clin. Microbiol. Rev. 10:1997;720-741.
2. Kuipers E.J. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment. Pharmacol. Ther. 11:(Suppl. 1):1997;71-88.
3. Gisbert J.P., Pajares J.M. Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment. Pharmacol. Ther. 16:2002;1047-1057.
4. Debets-Ossenkopp Y.J., Herscheid A.J., Pot R.G., Kuipers E.J., Kusters J.G., Vandenbroucke-Grauls C.M.J.E. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J. Antimicrob. Chemother. 43:1999;511-515.
5. Megraud F., Marshall B.J. How to treat Helicobacter pylori. First-line, second-line, and future therapies. Gastroenterol. Clin. North Am. 29:2000;759-773.
6. Gisbert J.P., Pajares J.M. Helicobacter pylori therapy: first-line options and rescue regimen. Dig. Dis. 19:2001;134-143.
7. Goodwin C.S. Antimicrobial treatment of Helicobacter pylori infection. Clin. Infect. Dis. 25:1997;1023-1026.
8. Brodersen D.E., Clemons W.M. Jr., Carter A.P., Morgan-Warren R.J., Wimberly B.T., Ramakrishnan V. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell. 103:2000;1143-1154.
9. Chopra I., Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65:2001;232-260.
10. Mendonça S., Ecclissato C., Sartori M.S., Godoy A.P., Guerzoni R.A., Degger M., Pedrazzoli J. Jr. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter. 5:2000;79-83.
11. Realdi G., Dore M.P., Piana A., Atzei A., Carta M., Cugia L., Manca A., Are B.M., Massarelli G., Mura I., Maida A., Graham D.Y. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter. 4:1999;106-112.
12. Wu H., Shi X.D., Wang H.T., Liu J.X. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin. J. Antimicrob. Chemother. 46:2000;121-123.
13. Gerrits M.M., de Zoete M.R., Arents N.L., Kuipers E.J., Kusters J.G. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 46:2002;2996-3000.
14. Trieber C.A., Taylor D.E. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J. Bacteriol. 184:2002;2131-2140.
15. Dailidiene D., Bertoli M.T., Miciuleviciene J., Mukhopadhyay A.K., Dailide G., Pascasio M.A., Kupcinskas L., Berg D.E. Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob. Agents Chemother. 46:2002;3940-3946.
16. Godoy A.P., Ribeiro M.L., Benvengo Y.H.B., Vitiello L., Miranda M.C.B., Mendonça S., Pedrazzoli J. Jr. Analysis of antimicrobial susceptibbility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol. 3:2003;20.
17. Silva F.M., Eisig J.N., Chehter E.Z., Silva J.J., Laudanna A.A. Omeprazole, furazolidone, and tetracycline: an eradication treatment for resistant Helicobacter pylori in Brazilian patients with peptic ulcer disease. Rev. Hosp. Clin. Fac. Med. Sao Paulo. 57:2002;205-208.
18. Megraud F., Lehn N., Lind T., Bayerdorffer E., O'Morain C., Spiller R., Unge P., Veldhuyzen van Zanten S.J., Wrangstadh M., Burman C.F. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob. Agents Chemother. 43:1999;2747-2752.
19. Gerrits M.M., Berning M., van Vliet A.H.M., Kuipers E.J., Kusters J.G. Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 47:2003;2984-2986.
20. Tomb J.F., White O., Kerlavage A.R., Clayton R.A., Sutton G.G., Fleischmann R.D., Ketchum K.A., Klenk H.P., Gill S., Dougherty B.A., Nelson K., et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 388:1997;539-547.
21. Alm R.A., Ling L.S., Moir D.T., King B.L., Brown E.D., Doig P.C., Smith D.R., Noonan B., Guild B.C., deJonge B.L., et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature. 397:1999;176-180.
22. Lee A., O'Rourke J., De Ungria M.C., Robertson B., Daskalopoulos G., Dixon M.F. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology. 112:1997;1386-1397.